TR200000930T2 - Büyüme hormonu sekretagogları. - Google Patents

Büyüme hormonu sekretagogları.

Info

Publication number
TR200000930T2
TR200000930T2 TR2000/00930T TR200000930T TR200000930T2 TR 200000930 T2 TR200000930 T2 TR 200000930T2 TR 2000/00930 T TR2000/00930 T TR 2000/00930T TR 200000930 T TR200000930 T TR 200000930T TR 200000930 T2 TR200000930 T2 TR 200000930T2
Authority
TR
Turkey
Prior art keywords
growth hormone
hormone secretagogues
compounds
new
relates
Prior art date
Application number
TR2000/00930T
Other languages
English (en)
Inventor
Alan Dodge Jeffrey
Lee Hauser Kenneth
Louis Heiman Mark
Alan Jones Scott
Arthur Alt Charles
Uhlman Bryant Henry
Daniel Cohen Jeffrey
Densmore Copp James
Harlan Gritton William
Nickolaus Jungheim Louis
Willis Lugar Charles Iii
Stephen Muehl Brian
David Palkowitz Alan
Michael Ratz Andrew
Anthony Rhodes Gary
Lewis Robey Robert
Alan Shepherd Timothy
Jeff Thrasher Kenneth
George Trankle William
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200000930T2 publication Critical patent/TR200000930T2/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42Nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/40Acylated on said nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bulus memelilerde endojen büyüme hormonu düzeylerinin degistirilmesinde kullanilan yeni bilesiklerle ilgilidir. Bulus ayrica bu bilesiklerin sentezinde kullanilan yeni ara ürünlerle ve bu sentezlerde kullanilan yeni islemlerle ilgilidir. Ayrica sözü geçen bilesikler kullanilarak memelilerin tedavisi için yöntemler açiklanmaktadir.
TR2000/00930T 1997-08-19 1998-08-19 Büyüme hormonu sekretagogları. TR200000930T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5614297P 1997-08-19 1997-08-19

Publications (1)

Publication Number Publication Date
TR200000930T2 true TR200000930T2 (tr) 2000-11-21

Family

ID=22002443

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00930T TR200000930T2 (tr) 1997-08-19 1998-08-19 Büyüme hormonu sekretagogları.

Country Status (24)

Country Link
EP (1) EP0933365A3 (tr)
JP (1) JP2001515046A (tr)
KR (1) KR20010027947A (tr)
CN (1) CN1243567C (tr)
AR (1) AR018010A1 (tr)
AU (1) AU738204B2 (tr)
BR (1) BR9811948A (tr)
CA (1) CA2302467A1 (tr)
CO (1) CO5121066A1 (tr)
EA (1) EA002746B1 (tr)
HR (1) HRP20000090A2 (tr)
HU (1) HUP0002392A3 (tr)
ID (1) ID25000A (tr)
IL (1) IL134596A0 (tr)
MY (1) MY138258A (tr)
NO (1) NO20000823L (tr)
NZ (1) NZ502947A (tr)
PE (1) PE115999A1 (tr)
PL (1) PL338883A1 (tr)
TR (1) TR200000930T2 (tr)
TW (1) TW577879B (tr)
UA (1) UA58472C2 (tr)
WO (1) WO1999008699A1 (tr)
ZA (1) ZA987385B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
EP1112071A4 (en) * 1998-08-18 2003-03-19 Lilly Co Eli SECRETAGOGUES OF GROWTH HORMONES
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6417397B1 (en) * 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US20040106665A1 (en) * 2000-10-13 2004-06-03 Kress Thomas Joseph Resolution process for preparation of substantially pure (r) and (s) enantiomers of 2-(4-nitroimidazolyl)-4-methodxyphenylpropionic acid and salts thereof
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
AU2003218337A1 (en) 2002-04-09 2003-10-27 Eli Lilly And Company Growth hormone secretagogues
WO2004060371A1 (en) * 2002-12-18 2004-07-22 Fmc Corporation N-(substituted arylmethyl)-4-(disubstituted methyl) piperidines and pyridines
EP1730119B1 (en) 2004-03-23 2008-06-25 Pfizer Products Incorporated Imidazole compounds for the treatment of neurodegenerative disorders
KR20080040010A (ko) 2005-09-22 2008-05-07 화이자 프로덕츠 인코포레이티드 신경계 질환 치료용 이미다졸 화합물
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
SG11201405810UA (en) 2012-05-03 2014-11-27 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
US9763957B2 (en) 2013-07-18 2017-09-19 Novartis Ag Autotaxin inhibitors
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106687447B (zh) * 2014-08-29 2020-06-02 东京应化工业株式会社 咪唑化合物、金属表面处理液、金属的表面处理方法、及层合体的制造方法
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN107286041A (zh) * 2016-04-01 2017-10-24 成都川科化工有限公司 一种n,n-二乙基甲酰胺的制备方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN110128285B (zh) * 2019-06-24 2022-03-01 华北制药股份有限公司 D-苯甘氨酸甲酯盐酸盐/d-二氢苯基甘氨酸甲酯盐酸盐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
SK282166B6 (sk) * 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
CN1136278A (zh) * 1993-10-19 1996-11-20 麦克公司 双膦酸盐与生长激素促分泌素的组合
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ZA966891B (en) * 1995-08-21 1998-02-16 Lilly Co Eli 2-acylaminopropanamines as growth hormone secretagogues.
EP0761220A1 (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues

Also Published As

Publication number Publication date
EA002746B1 (ru) 2002-08-29
WO1999008699A1 (en) 1999-02-25
EA200000239A1 (ru) 2000-10-30
MY138258A (en) 2009-05-29
NO20000823D0 (no) 2000-02-18
EP0933365A2 (en) 1999-08-04
AU738204B2 (en) 2001-09-13
CA2302467A1 (en) 1999-02-25
BR9811948A (pt) 2000-08-22
UA58472C2 (uk) 2003-08-15
NO20000823L (no) 2000-04-12
IL134596A0 (en) 2001-04-30
HRP20000090A2 (en) 2001-04-30
CN1276727A (zh) 2000-12-13
AU9025698A (en) 1999-03-08
TW577879B (en) 2004-03-01
CN1243567C (zh) 2006-03-01
HUP0002392A2 (hu) 2000-10-28
ZA987385B (en) 2000-04-18
KR20010027947A (ko) 2001-04-06
NZ502947A (en) 2001-11-30
PE115999A1 (es) 1999-11-26
PL338883A1 (en) 2000-11-20
JP2001515046A (ja) 2001-09-18
CO5121066A1 (es) 2002-01-30
AR018010A1 (es) 2001-10-31
HUP0002392A3 (en) 2000-11-28
EP0933365A3 (en) 2003-03-19
ID25000A (id) 2000-09-07

Similar Documents

Publication Publication Date Title
TR200000930T2 (tr) Büyüme hormonu sekretagogları.
ATE271058T1 (de) Mycophenol bisphosponatverbindungen
DZ3482A1 (fr) Secretagogues de l'hormone de croissance
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
TR199900239T2 (tr)
MX9703564A (es) Inhibidores de proteasa multicatalitica.
ATE290014T1 (de) Festphasen-peptidsynthese
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
TR200100426T2 (tr) Nematisit pirazoller
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
TR199800956T1 (tr) Yeni Indol-2, 3-diyon-3- oksim türevleri.
TR199800243T1 (tr) Prolil endopeptidaz inhibitörleri.
SE9604582D0 (sv) Novel compounds
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
TR199700416A2 (tr) Fluorinlenmis vitamin D3 analoglari.
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen
TR200002999T2 (tr) 4-değiştirilmiş-1H-indol-glioksamidlerin hazırlanmasına mahsus yöntem
PT950056E (pt) N-(piridinilamino) isoindolinas e compostos relacionados
DE59809344D1 (de) Disubstituierte biphenyloxazoline
TR200001969T2 (tr) 17-Değiştirilmemiş 16.beta.-ariloksi 4-azasteroidlerin sentezleri için arabileşikler ve işlem.
MX9704836A (es) Proceso para la fabricaciom de acetonilbenzamidas.
SE9603726D0 (sv) Novel compounds